We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bioventix plc (BVXP) Ordinary 5p

Sell:3,700.00p Buy:3,800.00p 0 Change: 40.00p (1.07%)
FTSE AIM 100:0.78%
Market closed Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:3,700.00p
Buy:3,800.00p
Change: 40.00p (1.07%)
Market closed Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:3,700.00p
Buy:3,800.00p
Change: 40.00p (1.07%)
Market closed Prices as at close on 21 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.

Contact details

Address:
7 Romans Business Park, East Street
FARNHAM
GU9 7SX
United Kingdom
Telephone:
+44 (01252) 728001
Website:
https://www.bioventix.com/

Important dates

Future events
AGM 25 December 2024 25/12/24
Past events
Interim dividend payment date 21 November 2024 21/11/24
Annual report 08 November 2024 08/11/24
Interim ex-dividend date 07 November 2024 07/11/24
Drilling report 28 October 2024 28/10/24
Final results 28 October 2024 28/10/24
Interim dividend payment date 26 April 2024 26/04/24
Interim ex-dividend date 11 April 2024 11/04/24
Interim results 25 March 2024 25/03/24
AGM 07 December 2023 07/12/23
Interim dividend payment date 24 November 2023 24/11/23

General stock information

EPIC:
BVXP
ISIN:
GB00B4QVDF07
Market cap:
£193.65 million
Shares in issue:
5.22 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Peter Harrison
    Chief Executive Officer, Executive Director
  • Bruce Hiscock
    Chief Financial Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.